CYP2D6 rs5030869: What Your Genotype Means
The genetic variant rs5030869 is a rare single nucleotide polymorphism located in the CYP2D6 gene that disrupts critical pre-mRNA splicing. It serves as the defining marker for the CYP2D6*11 haplotype, which completely abolishes the enzymatic activity of the encoded drug-metabolizing protein. Carrying this nonfunctional allele can contribute to an intermediate or poor metabolizer phenotype for numerous widely prescribed medications.
What each genotype means
| Genotype | What the research suggests | Reading |
|---|---|---|
| GG | You do not carry the splice-disrupting variant at rs5030869. Your enzyme function from this specific position is unaffected, though your overall CYP2D6 status still depends on other genetic variants in the gene. | Informational |
| GC | You carry one copy of the variant defining the nonfunctional CYP2D6*11 allele. This chromosome produces inactive enzyme, which can lower your overall metabolic capacity toward CYP2D6 substrate medications depending on your other allele. | Higher attention |
| CC | You carry two copies of the rs5030869 variant, corresponding to a homozygous *11/*11 state. Both alleles fail to produce functional CYP2D6 enzyme, resulting in a poor metabolizer status for CYP2D6-processed medications. | Higher attention |
Molecular Identity and Biological Location
The single nucleotide polymorphism rs5030869 is located within the CYP2D6 gene on chromosome 22q13.2. Structurally, it resides at a critical splice junction (described historically as c.883G>C or 883G>C in the M33388 reference sequence), disrupting normal pre-mRNA splicing. Because accurate splicing is required to generate the full-length enzyme, this nucleotide substitution leads to an aberrant, nonfunctional transcript. In pharmacogenomic nomenclature established by PharmVar and the Pharmacogenomics Knowledgebase, rs5030869 is the defining core variant for the CYP2D6*11 haplotype. When an individual inherits this allele, that specific chromosomal copy yields zero enzymatic activity, classifying it as a null or no-function allele.
The Pharmacogenomic Role of CYP2D6
The CYP2D6 gene encodes cytochrome P450 2D6, a liver enzyme responsible for metabolizing approximately 20% to 25% of all clinically prescribed medications. Its substrate profile is extensive, encompassing antidepressants (such as fluoxetine and venlafaxine), antipsychotics, beta-blockers, antiarrhythmics, tamoxifen, and opioid prodrugs such as codeine and tramadol. CYP2D6 activity is inherited in an autosomal codominant fashion, with each copy contributing an activity score between 0 and 1 (or higher if duplicated). The combination of both inherited alleles determines whether an individual is an ultrarapid, normal, intermediate, or poor metabolizer, dictating how quickly these therapeutic agents are cleared or converted into active compounds.
Clinical Evidence and Phenotypic Impact
The Clinical Pharmacogenetics Implementation Consortium (CPIC) and the Dutch Pharmacogenetics Working Group (DPWG) classify CYP2D6*11 as a no-function allele with an assigned activity score of 0. Clinical evidence specifically measuring rs5030869 across massive populations is limited due to its low frequency, but its molecular mechanism is well characterized. If paired with another no-function allele (such as CYP2D6*3, *4, or *5), an individual is predicted to be a poor metabolizer. Poor metabolizers face increased risks of drug toxicity and side effects from standard doses of active drugs, or reduced efficacy from prodrugs like codeine, which rely on CYP2D6 bioactivation into morphine to provide analgesia.
Population Frequency and Diversity
CYP2D6*11 and its defining variant rs5030869 are exceedingly rare across global populations. Large-scale genomic databases, including gnomAD and European sequencing cohorts, observe a minor allele frequency typically below 0.005 (0.5%), with many cohorts reporting frequencies under 0.1%. While CYP2D6 features significant ancestral diversity—such as high frequencies of the reduced-function *10 allele in East Asian ancestries and *17 or *29 in African ancestries—rs5030869 has predominantly been detected at very low levels in individuals of European descent. Because of its rarity, it is not always included on basic targeted genotyping panels, though comprehensive sequencing readily captures it.
Navigating Results: What Readers Should Know
Learning that you carry rs5030869 does not constitute a disease diagnosis; it simply offers insight into your body's potential drug-processing speed. However, an accurate CYP2D6 phenotype cannot be determined from rs5030869 alone. It requires comprehensive diplotype testing that evaluates the opposite chromosome as well as potential copy number variants, such as whole-gene duplications or deletions. Most importantly, pharmacogenomic findings should never prompt independent medication changes. If your genetic testing indicates that you carry a no-function allele, share the laboratory report with a physician or clinical pharmacist to evaluate whether dosing adjustments or alternative therapies are warranted.
How common is this variant?
The rs5030869 variant is exceptionally rare across all surveyed global ancestries, exhibiting a minor allele frequency of less than 0.005 (<0.5%) in European cohorts and appearing rarely or not at all in other ancestral populations.
Frequently asked questions
Does having rs5030869 mean I have a health condition?
No, carrying rs5030869 is not associated with an illness or health defect. It is a pharmacogenomic variant that strictly influences how your liver metabolizes certain medications.
What medications are affected by the CYP2D6 gene?
CYP2D6 processes a large variety of common medications, including selective serotonin reuptake inhibitors, tricyclic antidepressants, beta-blockers, tamoxifen, and certain pain relievers like codeine and tramadol. Your specific response depends on whether the medication is cleared by the enzyme or activated by it.
Can rs5030869 alone tell me my exact metabolizer category?
No, determining your full metabolizer phenotype requires looking at both inherited CYP2D6 alleles and checking for copy number variations. Carrying one copy of rs5030869 means one allele is nonfunctional, but the other allele determines the remainder of your enzyme activity.
Should I stop taking my prescription if I carry this variant?
Never discontinue or alter the dose of any prescription medication based on direct-to-consumer genetic data. Always bring your raw genetic findings to your prescribing doctor or a clinical pharmacist for proper interpretation and guidance.
Sources & further reading
Educational information only, last refreshed 9/7/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs5030869?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29